NCT05311228

The Efect of Azithromicyn on Bronchopulmonary Displasia in Extremely Preterm and Very Preterm Infant

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Indonesia University · Academic / Other
• Sex: All
• Age: 25 Weeks – 32 Weeks
• Healthy volunteers: Not accepted

Summary

This study was to see the effectiveness of azithromycin in preventing the incidence of bronchopulmonary dysphasia in extremely preterm and very premature infants. Inclusion criteria were infants with a gestational age of 25-31 weeks 6 days who experienced respiratory distress and their families had agreed to participate in the study, then randomized. The intervention was in the form of giving azithromycin in the intervention group and no intervention was carried out in the control group and then followed up to 36 weeks PMA

Conditions

• Bronchopulmonary Dysplasia
• Intraventricular Hemorrhage
• Necrotizing Enterocolitis

Interventions

Type	Name	Description
DRUG	Azithromycin Powder	Azithromicyn intravena for 14 days

Timeline

• Start date: 2021-06-08
• Primary completion: 2022-03-01
• Completion: 2022-04-01
• First posted: 2022-04-05
• Last updated: 2024-03-08

Locations

1 site across 1 country: Indonesia